Compositions having improved bioavailability of therapeutics
AssigneeTRx Biosciences Limited
InventorsJohn Brew, Daniel Gooding, Robin M. Bannister
Life of this patent
Estimating the term…
Abstract
The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.
Claims21
A pharmaceutical composition comprising:
- a) one or more pharmaceutically active agents selected from the group consisting of an abiraterone, an amlexanox, an aprepitant, an auranofin, a cannabidiol, a diclofenac, an eliglustat, an ezetimibe, a fenofibrate, an ibuprofen, an icatibant, a mebendazole, a mefenamic acid, a midostaurin, a naproxen, a niflumic acid, a nintedanib, an olaparib, a pirfenidone, a pitolisant, a telmisartan, tetrahydrocannabinol, and combinations thereof;
- and
- b) about 45% to about 95% by weight of the pharmaceutical composition of one or more glycerolipids, the one or more glycerolipids being one or more saturated C10-C22 triglycerides and a mixture of unsaturated C14-C22 monoglycerides, unsaturated C14-C22 diglycerides, and unsaturated C14-C22 triglycerides;
- and
- c) about 1.0% to about 8.0% by weight of the pharmaceutical composition of one or more free C14-24 fatty acid surfactants, about 15% to about 40% by weight of the pharmaceutical composition of one or more free C14-24 fatty acids, or both the one or more free C14-24 fatty acid surfactants and the one or more free C14-24 fatty acids;
- and
- wherein the pharmaceutical composition is an anhydrous formulation;
- and
- wherein the pharmaceutical composition is not an emulsion.
Dependencies are inferred from the claim text.